| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba4ce9358b36b500b205d65686b702c9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70532
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-103
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2022-03-31^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7d9d6cfb79ce51ab9861104eef26cd6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15cbad8698cdb1dc4fa05dcd1f81ea60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acee1f2a33109a5ee5edcbe5b9d3cc4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f420c749ce89edde0c81ffb5b75a35b6 |
| publicationDate |
2022-10-06^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022212775-A1 |
| titleOfInvention |
Pd-l1 as a predictive marker for therapy in cancer |
| abstract |
Methods for treating and/or prognosing breast cancer and breast cancer recurrence are provided. The method includes obtaining a tissue sample of a tumor from a breast cancer patient, determining an expression level of one or more markers (for example PD-1 and/or PDL1) in the sample, and providing intensified treatment to the subject based on the level of (for example) PD-1 and/or PD-L1. The intensified treatment can be intensified radiotherapy treatment. |
| priorityDate |
2021-04-01^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |